Tazemetostat (Tazverik™), a first-in-class, small molecule enhancer of zeste homolog 2
(EZH2) inhibitor, received accelerated approval in January 2020 in the USA for the treatment …

The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation and survival. Overexpression and overactivation of members …

Innate and acquired resistance towards the conventional therapeutic regimen imposes a
significant challenge for the successful management of cancer for decades. In patients with …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

The reversible and precise temporal and spatial regulation of histone lysine
methyltransferases (KMTs) is essential for epigenome homeostasis. The dysregulation of …

Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …

Acquired drug resistance represents a major obstacle to tyrosine kinase inhibitor (TKI)-
induced differentiation therapy of radioiodine-refractory papillary thyroid cancer (RR-PTC); …

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively
increasing incidence rate has been observed in recent years, with 95% of thyroid cancer …